Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00012064 · ClinicalTrials.gov registry record · Phase 1
Vaccine Therapy in Treating Patients With Stage IV or Recurrent Melanoma
A Phase 1 study, sponsored by Lisata Therapeutics.
- Completed
- Registry status
- Phase 1
- Development phase
- 56
- Enrollment target
NCT00012064 is a Phase 1 study that has completed, run by Lisata Therapeutics. The registered enrollment target is 56 participants.
The verdict
NCT00012064, a Phase 1 study, has completed, sponsored by Lisata Therapeutics.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 56 participants
- Enrollment target
Study Summary
RATIONALE: Vaccines made from a person's cancer cells may make the body build an immune response to kill tumor cells. PURPOSE: Phase I/II trial to study the effectiveness of vaccine therapy in treating patients who have stage IV or recurrent melanoma.
Interventions
- BIOLOGICAL therapeutic autologous dendritic cells
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 56 participants |
| Start Date | 2000-07 |
| Est. Completion | 2011-04 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00012064
The ClinicalTrials.gov registry entry for NCT00012064 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 56 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Lisata Therapeutics, which has 12 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which therapeutic autologous dendritic cells is the first listed.
NCT00012064 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00012064 about?
NCT00012064 is a clinical study titled "Vaccine Therapy in Treating Patients With Stage IV or Recurrent Melanoma". RATIONALE: Vaccines made from a person's cancer cells may make the body build an immune response to kill tumor cells. PURPOSE: Phase I/II trial to study the effectiveness of vaccine therapy in treating patients who have stage IV or recurrent melanoma.
What is the current status of trial NCT00012064?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 56 participants. The study started on 2000-07. Estimated completion is 2011-04.
What interventions are being tested in trial NCT00012064?
The interventions under investigation include: therapeutic autologous dendritic cells (BIOLOGICAL).
Who is sponsoring clinical trial NCT00012064?
This trial is sponsored by Lisata Therapeutics, which has 12 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.